Celiac disease (CD) is an autoimmune disease characterized by inflammation of the intestinal mucosa due to an immune response to wheat gliadins. Some gliadin peptides are resistant to intestinal digestion (e.g., A-gliadin P31-43) and induce a stress/innate immune response, but the reason why they are dangerous in the intestines of patients with CD is unknown. In the present study, P31-43 activated IFN-α, a mediator of the innate immune response in CD, in the intestine of subjects with CD and an enterocyte cell line, CaCo-2. P31-43 cooperated with a viral ligand to activate the TLR7 pathway by interfering with endocytic trafficking. Based on these results, the vesicular pathway regulates the innate/inflammatory response to viral ligands and bioactive dietary peptides. Suggesting that together with viral infections, alimentary proteins able to mimic and potentiate the innate immune response to viruses, can trigger an autoimmune disease such as CD.
delay prolongs their activation, resulting in increased proliferation, actin remodelling and other biological effects. The alteration of the recycling pathway can direct more IL15 receptor alpha (IL15Rα) to the cell surface, enhancing the trans presentation of IL15/IL15Rα in epithelial cells 7 . Type 1 interferons also play a role in the loss of oral tolerance to gluten in patients with CD. In fact, interferon-alpha (IFN-α) is dysregulated in patients with CD, and IFN-α therapy can induce CD in some genetically susceptible individuals. In addition, rotavirus infections are associated with an increased incidence of CD 13 . Moreover, the combination of viral infections and dietary gliadin causes an enteropathy in normal mice 14 . The cellular rotavirus receptor is Toll-like receptor 7 (TLR7) 15 . TLR7 is an endosomal receptor that specifically recognizes the viral mRNA and is regulated by endosomal trafficking. The signalling pathway initiated by TLR7 when it is engaged by selected viral ligands, including the TLR7-specific ligand loxoribine (LOX), induces the formation of a myeloid differentiation primary response 88 (MyD88)/TLR7 complex that requires endosomal trafficking to be activated. Subsequently, the activated complex induces the phosphorylation of mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) activation, ultimately increasing the levels of IFN-α and myxovirus resistance protein 1 (MxA), an antiviral protein that can embed the viral particles 16 . Interestingly, HRS is also a key factor in endosomal TLR7 and Toll-like receptor 9 (TLR9) trafficking; in fact, it is necessary for the ubiquitin-dependent targeting of TLR9 to the lysosomes 17 . Based on these observations, mechanisms regulating vesicular trafficking are central to viral infections response.
In the present study, we investigated whether the A-gliadin peptide P31-43 could mimic and reinforce the IFN-α mediated innate immune response to viruses in biopsies from patients with CD and a gliadin-responsive intestinal cell line, CaCo-2, by interfering with endocytic trafficking.
Results
In small intestinal biopsies, MxA and IFN-α are expressed at higher levels in patients with CD on a GCD and the expression of both proteins is induced by P31-43 in patients with CD on a gluten-containing diet (GCD) or a gluten-free diet (GFD). The IFN-α pathway was activated in CD biopsies in previous reports 13, 18 . We confirmed these observations by analysing levels of the MxA protein in biopsies from patients with CD on a GCD or GFD. MxA levels were only increased in patients with CD on a GCD (Fig. 1A) . Specifically, the ratio of MxA to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) proteins increased from 0.2 ± 0.2 in the controls to 0.9 ± 0.59 (p = 0.006) in patients on a GCD, whereas it was only 0.28 ± 0.39 in the biopsies from patients on a GFD. In addition, levels of the IFN-α protein were increased in patients with CD on a GCD (Fig. 1B) . In vitro P31-43, but not P57-68, treatment increased MxA levels in cultures of the intestinal biopsies from patients with CD on either diet. Values for cultures obtained from subjects on a GCD (0.3 ± 0.14, p = 0.038) and GFD (0.6 ± 0.10, p = 0.039) were greater than values for cultures of the untreated biopsies (0.16 +/− 0.14 and 0.3 +/− 0.12, respectively). Levels of the IFN-α 7 and 17 mRNAs were also increased after treatment with P31-43 in biopsies from patients with CD on a GCD (data not shown). In cultured biopsies from the control subjects (CTR), P31-43 had no effect on the levels of the MxA protein (Fig. 1C ) or IFN-α 7 and 17 mRNAs (data not shown). Thus, the IFN-α pathway was activated by the gliadin peptide P31-43 in the small intestine of patients with CD.
Similar to the viral ligand LOX, P31-43 activates the TLR7 pathway. We investigated the effects of the gliadin peptide P31-43 on CaCo-2 cells, an intestinal epithelial cell line that is responsive to gliadin, to obtain a better understanding of the mechanisms by which this peptide activates the IFN-α pathway. We first investigated the specificity and toxicity of the P31-43 peptide in CaCo-2 cells. The specificity of the effects of P31-43 was confirmed by examining extracellular signal-regulated kinase (ERK) activation in CaCo-2 cells after treatment with permuted P31-43 (alanine scanning). Most of the mutations reduced ERK phosphorylation (pY-ERK) (Supplemental Fig. 1A ). The toxicity of P31-43 was analysed using Trypan blue staining, a vital colorant. As shown in Supplemental Fig. 1B , treatment with 100 μg/ml P31-43 and P57-68 peptides had no effect on cell viability. Interestingly, the amount of P31-43 used in our experiments was not substantially different from the amount that is presumably generated in the intestine during the digestion of wheat flour 6 . Moreover, a dose response assay using pY-ERK levels as a readout of the effects of P31-43 and P57-68 showed that treatment with 50 and 100 μg/ml P31-43 activated ERK. P57-68 did not activate ERK at any concentration tested (Supplemental Fig. 1C ). We compared the effects of P31-43 and the viral ligand LOX on the activation of the TLR7 pathway in CaCo-2 cells. LOX specifically activates the MyD88-dependent TLR7 signalling pathway via TLR7 16 . Moreover, CaCo-2 cells in general and, specifically, our clone do not express the other endosomal receptor, TLR9 ( 19 and not shown), confirming that the CaCo-2 cell line is a good model with which to study TLR7 activation in epithelial intestinal cells. We compared the effects of P31-43 on the activation of the TLR7 pathway in CaCo-2 cells with those of LOX, beginning with the formation of the MyD88/TLR7 complex and subsequent activation of mitogen-activated protein kinases (MAPKs). Figure 2A shows the increase in formation of the MyD88/TLR7 complex induced by the viral ligand LOX and by P31-43 after stimulation for 30 min or 3 h. The amount of TLR7 in the complex with MyD88 in CaCo-2 cells increased from 0.16 ± 0.13 in the untreated sample to 1.8 ± 0.33 and 2 ± 0.47 in samples treated with LOX for 30 min or 3 h, respectively. Similarly, the gliadin peptide P31-43 induced a comparable increase in the level of TLR7 in the complex with MyD88 at 30 min (1.5 ± 0.53) and 3 h (1.2 ± 0.49). We next investigated the effects of LOX and P31-43 on the levels of the TLR7 and MyD88 proteins and found that TLR7 levels were significantly increased in cells treated with LOX for 6 h, (p < 0.01) or P31-43 for 30 min (p < 0.001) or 3 h (p < 0.05). MyD88 levels were also increased at all time points after LOX stimulation. In contrast, after P31-43 treatment, increases in the MyD88 levels were statistically significant only after 30 min of stimulation (Fig. 2B) . The time-dependent differences in the effects of LOX and P31-43 potentially suggest that the mechanisms through which each stimulus exerts its effects are not the same. The MyD88/TLR7 complexes induced both by LOX and P31-43 could activate downstream signalling by activating MAPKs, ERK, c-Jun N-terminal kinase (JNK) and protein 38 (p38). Specifically, as shown in Fig. 2C , LOX and P31-43 induced ScIEnTIFIc RepoRts | (2018) 8:10821 | DOI:10.1038/s41598-018-28830-y similar increases in the levels of the phosphorylated forms of pY-ERK, JNK (pY-JNK) and p38 (pY-p38) with very similar kinetics. Based on these data, P31-43 activates the same TLR7 pathway in intestinal epithelial cells that is specifically activated by the viral ligand LOX.
P31-43 and the viral ligand LOX induce the expression of markers of the activation of inflammation and innate immunity.
Activation of TLR7 and 9 leads to an innate immune response (increased IFN-α levels) and an inflammatory response (NF-κB activation) 20 . LOX and P31-43 treatments increased NF-κB indicating that the activation of the IFN-α pathway depended on the TLR7 activation in response to both LOX and P31-43 treatments. A control scrambled siRNA had no effect on the P31-43-or LOX-induced increases in levels of the MxA, TLR7 and MyD88 proteins (Fig. 4C ). Silencing of TLR7 and MyD88 proteins reduced the levels of the TLR7 and MyD88 proteins. Silencing of TLR7 had no effect on levels of the MyD88 protein, and silencing of MyD88 had no effect on levels of the TLR7 protein (Fig. 4D) .
As shown in our previous studies, P31-43 activates EGFR and other receptors by delaying their intracellular decay through its effect on vesicular trafficking 9,10,12 . Interestingly, the EGFR receptor complexed with TLR7 after treatment with LOX or P31-43, as shown in Supplemental Fig. 3 . This finding confirms that EGFR transduces signals from several different receptors.
P31-43 and LOX treatments delay TLR7 trafficking in the early endocytic compartment.
Viruses can interfere with vesicular trafficking at various levels during the infection of a cell 20 . In particular, the MyD88/TLR7 complex that forms in response to the viral ligand LOX requires endosomal trafficking for activation 16 . Moreover, P31-43 is known to delay endocytic trafficking from early to late endocytic vesicles [10] [11] [12] . We compared the trafficking of TLR7 from early vesicles (early endocytic antigen, EEA1-positive) to late vesicles (lysosome-associated membrane proteins, LAMP 2-positive) after LOX and P31-43 stimulation. TLR7 exhibited greater co-localization with EEA1 and less co-localization with LAMP2 in samples treated with either LOX and P31-43 than in the untreated sample (Supplemental Fig. 4 ). We evaluated the trafficking of TLR7 after P31-43 treatment in time-course experiments. P31-43, but not P57-68, delayed TLR7 trafficking in EEA1-positive vesicles after 3 h of treatment (Supplemental Fig. 5 ). In conclusion, both the viral ligand and the gliadin peptide P31-43 delayed TLR7 trafficking to the early endocytic compartment.
The delay of the maturation from early to late vesicles activated the TLR7 pathway. P31-43 delayed endocytic maturation by interfering with the correct localization of HRS on endocytic vesicles [10] [11] [12] . HRS is a key molecule required for the maturation of early to late endocytic vesicles 21 . We tested the hypothesis that the delay in the maturation of early to late vesicles could, per se, activate the TLR7 pathway. We tested this hypothesis by inducing a delay in the maturation of the vesicles through the silencing of the HRS protein (si-HRS) 12 and analysed the trafficking of TLR7 to the early and late compartments. Under these conditions, more TLR7 was co-localized with the EEA1-positive early vesicles ( Supplementary Fig. 4 ) and less with the LAMP2-positive late vesicles, similar to the effects described after LOX and P31-43 treatments ( Supplementary Fig. 4 ).
We next studied the effects of si-HRS on the activation of the TLR7 pathway. As read outs of TLR7 activation, we analysed the formation of the MyD88/TLR7 complex (Fig. 5A ), expression of MxA ( Fig. 5B ) and IFN-α ( Fig. 5C ) and the activation of NF-κB ( Fig. 5D ) after HRS silencing. Similar to the effects of the gliadin peptide P31-43 and LOX, the amount of TLR7 in complexes with MyD88 was significantly increased compared to the untreated sample (p = 0.03). Levels of the MxA (p = 0.02), IFN-α 7 (p = 0.0009) and 17 (p = 0.04) mRNAs and the phosphorylated form of NF-κB (p = 0.03) were increased after HRS silencing (Fig. 5 ). Additionally, levels of both the TLR7 and MyD88 proteins were increased after si-HRS treatment (Fig. 5B ). Control si-mRNA had no effect on HRS expression ( Fig. 5Bc ). In conclusion, the alterations in vesicular trafficking induced by si-HRS activated the TLR7 pathway and the IFN-α-mediated immune response, as well as NF-κB-mediated inflammation.
Discussion
In the present study, the undigested A-gliadin peptide P31-43 activated the IFN-α pathway in the intestines of patients with CD and in the gliadin-responsive 7,9,10,12,22-25 enterocyte cell line, CaCo-2.
P31-43 could induced the IFN-α-mediated innate immune response in CaCo-2 cells by activating the TLR7 pathway, similar to the viral ligand LOX. Both the viral ligand LOX and P31-43 delayed the trafficking of TLR7 from the early endocytic compartment. Moreover, P31-43 and LOX induced increased complex formation and levels of the TLR7 and MyD88 proteins, subsequently activating MAPKs, the innate immune response (increase in levels of IFN-α and the antiviral protein MxA), and an inflammatory response (increased phosphorylation of NF-κB). Finally, MyD88 and TLR7 silencing prevented complex formation and downstream pathway activation after either LOX or P31-43 treatment, indicating that complex formation is necessary for both stimuli to exert their effects. Interestingly, LOX and P31-43 cooperated to induce the activation of the IFN-α pathway. Specifically, when LOX and P31-43 were applied together at suboptimal concentrations, levels of both the MxA protein and IFN-α mRNA were increased. Cooperation between viral ligands and gliadin peptides, including P31-43, has been shown to induce enteropathy in mice 14, 26 .
Subsequently, we tested the hypothesis that P31-43 activated the IFN-α pathway by interfering with endocytic trafficking. This hypothesis is based on two main points. First, P31-43 delayed the maturation of the early to late endocytic vesicles by interfering with the correct endocytic localization of HRS 12 . Second, TLR7 is an endosomal receptor that responds to viral ligands by activating the IFN-α pathway, and its activation is regulated by vesicular trafficking 16, 17 .
These findings imply that vesicular trafficking plays a central role in modulating the innate immune activation in the host-pathogen response.
We induced a delay in the maturation of endocytic trafficking by silencing HRS, a master regulator of endocytic maturation 12 , to confirm the role of the delay in vesicular trafficking in IFN-α activation. HRS silencing mimicked all the measured effects of P31-43 on the TLR7 pathway: the delay in TLR7 trafficking to the early vesicles, the increases in the formation of the MyD88/TLR7 complex and protein levels, and the increases in levels of the IFN-α 7/17 mRNAs and MxA protein and NF-κB activation. These data are consistent with the hypothesis that the mechanism by which P31-43 activates the TLR7 pathway is mediated by a delay in endocytic trafficking. In fact, endocytosis exerts many effects on signalling. The endocytic pathway and signalling pathways are regulated reciprocally 27 . The TLR7/MyD88 complex could form in the delayed endocytic vesicles either because the delay in maturation alters the lipid composition and/or pH of vesicles or by other mechanisms present in cells 28 . Type 1 interferons play a role in the loss of oral tolerance to gluten in patients with CD 13, 18 . In the present study, we confirmed that IFN-α is a mediator of the innate immune response in patients with CD by showing an increase in the levels of the IFN-α and MxA proteins and the IFN-α 7 and 17 mRNAs in the intestinal biopsies from patients with CD on a GCD. The activation of the IFN-α pathway may have been induced by dietary gluten. In fact, the gliadin peptide P31-43 activated the IFN-α pathway in biopsies from patients with CD on a GFD and GCD, but not biopsies from controls, indicating a specific effect of gliadin on the intestines of patients with CD.
Interestingly, we observed a constitutive alteration of the vesicular trafficking in cells from patients with CD that is characterized by a delay in the maturation of early to the late vesicles, which predisposed the celiac cells to the activation of the innate immune response to gliadin (manuscript submitted). This finding could explain the specific effect of P31-43 on the activation of the IFN-α pathway in biopsies from patients with CD.
Based on the results presented here, viral infections and alimentary proteins, which are able to mimic and potentiate the innate immune response to viruses, trigger an autoimmune disease. In addition to CD, other autoimmune diseases result from the interactions of several factors, including genetics and the environment. Type 1 interferon activation is linked to autoimmunity not only in CD but also in several other human diseases, including type 1 diabetes 29 . Unlike CD, genetic polymorphisms that directly activate the type 1 interferon pathways are present in some of these diseases, although these alterations alone are not sufficient to induce the disease. The penetrance of these genetic profiles is determined by mostly unknown environmental factors, including disturbances in the microbiota and/or frequent viral infections 29 . In the present study, another environmental factor may be an alimentary protein, such as gliadin. Thus, gluten itself might be a risk factor for these conditions 30 .
Methods
Cell culture, materials and treatments. CaCo-2 cells were grown for 5-6 days in Dulbecco's Modified Eagle's Medium (DMEM) (GIBCO, San Giuliano Milanese, Italy) supplemented with 10% fetal calf serum (FCS, GIBCO), 100 units/ml of penicillin-streptomycin (GIBCO), and 1 mM glutamine (GIBCO). The medium was changed every two days. Lipopolysaccharide (LPS)-free synthetic peptides (Inbios, Naples, Italy) (>95% pure, evaluated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry) were obtained using Ultrasart-D20 filtration (Sartorius AG, Gottingen, Germany). The level of LPS in these peptides was below the detection threshold (i.e., <0.20 EU/mg), as assessed using the QCL-1000 kit (Cambrex Corporation, NJ). The sequence of P31-43 was LGQQQPFPPQQPY and that of P57-68 was QLQPFPQPQLPY. The peptides were used at a concentration of 100 μg/ml 10 . The guanosine analog/TLR7 ligand loxoribine (7-allyl-7,8 dihydro-8-oxoguanosine) from InvivoGen (San Diego, CA, USA) was used at a concentration of 1 mM 16 . EEA1 and Lamp staining. CaCo-2 cells were seeded on glass coverslips for 2 days. Than they were stained for 1 hour at room temperature with anti-TLR7 and anti EEA1 or LAMP2 antibody after fixation with 3% paraformaldeide for 5 minutes at room temperature and permeabilization with Triton (Biorad, Milan, Italy) 0.2% for 3 minutes at room temperature. Secondary antibodies Alexa-488 conjugated (Invitrogen, Milan, Italy) anti-rabbit for TLR; anti-goat Alexa-546 (Invitrogen, Milan, Italy) for EEA1; anti-mouse Alexa-546 (Invitrogen, Milan, Italy) for LAMP2 were added to the coverslips for 1 hour at room temperature. Nuclei were stained with Topro-3 iodide conjugate (642/661) (Invitrogen, Milan, Italy). The coverslips were then mounted on glass slides and observed by confocal microscope (LSM 510 Zeiss). Twenty to 30 cells were observed in each sample. Images were generated with a confocal microscope LSM 510 Zeiss. Co-localization analysis was performed with AIS Zeiss software. Magnification of the micrographs was the same for all the figures shown (63x objective, 2X zoom).
Colocalization analysis.
Samples were examined with a Zeiss LSM 510 laser scanning confocal microscope.
We used Argon/2 (458, 477, 488, 514 nanometers) and HeNe1 (543 nanometers) and HeNe2 (633 nanometers) excitation lasers, which were switched on separately to reduce cross-talk of the three fluorochromes. The green and the red emissions were separated by a dichroic splitter (FT 560) and filtered (515-to 540-nm band-pass filter for green and >610-nm long pass filter for red emission). A threshold was applied to the images to exclude about 99% of the signal found in control images. The weighted co-localization coefficient represents the sum of intensity of co-localizing pixels in channels 1 and 2 as compared to the overall sum of pixel intensities above threshold. This value could be 0 (no co-localization) or 1 (all pixels co-localize). Bright pixels contribute more than faint pixels. The co-localization coefficient represents the weighted colocalization coefficients of Ch1 (red) with respect to Ch2 (green) for each experiment 25,26 . Silencing experiments. Silencing Briefly, CaCo-2 cells were incubated in standard growth conditions, and 6 μg of siRNA was diluted in 1 ml of culture medium without serum to give a final siRNA concentration of 50 nM. Twenty microliters of HIPerFect Transfection reagent were added to the siRNA mixture with vortexing, and the transfection mixture was added drop wise onto the cells and incubated for 72 h. The cells were then processed for immunoprecipitation and for Western blot (WB) analysis.
Western blotting. CaCo-2 cells grown as before were stimulated with P31-43 or LOX for various times at 37 °C. The cells were washed twice and resuspended in lysis buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 5 mM MgCl 2 , 150 mM NaCl, 1% Triton, 1 mM PMSF, 1 mM VO 4 , 100× Aprotinin, and 50× LAP, all purchased from Sigma, Milan, Italy, except LAP, which was obtained from Roche, Milan, Italy). The cell lysates were analyzed using SDS-PAGE with a standard running buffer (25 mM Trizma, 192 mM Glycine, and 0.1% SDS) and were transferred onto nitrocellulose membranes (Whatman Gmbh, Dassel, Germany) using transfer buffer (25 mM Trizma, 192 mM Glycine, 0.1% SDS, and 20% methanol, all purchased from Sigma-Aldrich, Milan, Italy). The membranes were blocked with 5% non-fat dry milk and were probed with goat anti-MxA, rabbit anti-ERK1/2 and mouse anti-pY-ERK1/2, (Santa Cruz, Milan, Italy), mouse anti-IFN-α (RD System, Milan, Italy), mouse anti-GAPDH, mouse anti-tubulin (Sigma-Aldrich, Milan, Italy), rabbit anti-TLR7, rabbit anti-MyD88, rabbit anti-pY-NF-κB, rabbit anti-NF-κB, mouse anti-pY-p38, rabbit anti-p38, rabbit anti-pY-JNK and rabbit anti-JNK (Cell Signaling, Euroclene, Milan, Italy) and mouse anti-HRS (Alexix Biochemicals, San Diego, CA, USA). The bands were visualized using ECL (GE Healthcare, Amersham, Buckinghamshire, UK) with exposure times of 2-10 min. The band intensity was evaluated by integrating all the pixels of the band after subtraction of the background to calculate the average of the pixels surrounding the band 9 .
Immunoprecipitation. Lysates were prepared as described previously 9 , and the protein concentration was measured using a Bio-Rad protein assay kit (Munchen, Germany). Equal amounts of the cell lysates (2 mg of protein) were used for immunoprecipitation. MyD88 was immunoprecipitated for 24 h using the rabbit anti-MyD88 polyclonal antibody (Cell Signaling Euroclone, Milan Italy). EGFR was immunoprecipitated for 24 h using the anti-EGFR polyclonal antibody (Cell Signaling Euroclone, Milan, Italy). Following immunoprecipitation, the complexes were isolated using protein A/G magnetic beads and were washed 3× in lysis buffer. The pellet was resuspended in 35 μl of 2× Laemmli buffer (Sigma, Milan, Italy). The samples were heated to 95-100 °C for 5 minutes and were micro centrifuged for 1 minute at 14,000 × g. The samples were loaded (30 μl) onto SDS-PAGE gels (10%). The proteins were transferred to nitrocellulose membranes (Whatman Gmbh, Dassel, Germany), and the blots were probed for TLR7 with anti-TLR7 (Santa Cruz Biotech, Milan, Italy), for MyD88 with mouse anti-MyD88 (Abcam, Milan, Italy) and for EGFR with anti-EGFR polyclonal antibody (Cell Signaling Euroclone, Milan, Italy). PCR analysis. cDNAs were generated from the total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) 9 . The resulting cDNA samples were subjected to cycles of PCR amplification, followed by real-time PCR using TaqMan ® preAmp Master Mix Kit protocol (Applied Biosystems, PN 4366127, Foster City, CA, USA). Each TaqMan Gene Expression assay consisted of two sequence-specific PCR primers and a TaqMan assay-FAM dye-labelled MGB probe. Eighty nanograms of total cDNA was used for each replicate assay. Three replicates were run for each sample in a 96-well plate format. The endogenous control gene used was beta-2-microglobulin (B2 M). The assays were run with 2× Universal PCR Master Mix without UNG (uracil-N-glycosylase) using an Applied Biosystems 7300 Real-Time PCR System and universal cycling conditions (10 min at 95 °C; 15 sec at 95 °C, 1 min at 60 °C for 40 cycles).
Organ culture studies. For organ culture studies, biopsy fragments from the duodenum were obtained from CD patients with villous atrophy on GCD, controls, affected by gastroesophageal reflux, and CD patients on GFD. The age range for all subjects was 2 to 17 years. GFD patients had negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1). GCD-CD patients with villous atrophy (Marsh T3a-c) had a positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ( Table 1) . Anti-tTg antibodies were measured using the Eurospital kit, EU-tTG. Biopsy fragments were used to evaluate the expression of the MxA and IFN-α proteins using Western blotting. Intestinal biopsies from the GCD CD patients, the GFD CD subjects and control subjects were cultured 9 with P31-43 (100 μg/ml) or P57-68 (100 μg/ml) or medium alone for 24 h to examine MxA and IFN-α expression.
Ethical statements. The protocol for this study was approved by the Ethical Committee of the University "Federico II", Naples, Italy (ethical approval: C.E. n. 230/05). Biopsy fragments for organ culture studies were obtained from the duodenum of untreated patients with active and remission CD and controls affected by gastroesophageal reflux. Written informed consent was obtained from patients or from the next of kin, caretakers, or guardians on behalf of the minors/children participants involved in our study. The Authors confirm that all methods were performed in accordance with the relevant guidelines and regulations.
Statistical analyses. Graphpad prism 5 (Graphpad Software, San Diego, CA, USA) was used for statistical analysis and graphic representation. Statistical analyses of differences were performed using Student's t-test. A p value < 0.05 was considered statistically significant. One-way Anova, Bonferroni corrected (p value < 0.05 was considered statistically significant) was used for multiple comparisons as indicated in the figure legends.
